Company Profile
MiNK Therapeutics, Inc. Stock Price, News & Catalysts
- Ticker:
- INKT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
11.71 USD (+1.04%)
Close
Last updated: September 17, 2026
59.6M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, INKT closed up 1.04% at $11.71. No new same-company headline was identified in the current news window.
Company overview
Allogeneic iNKT Cell Therapy Company
MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines. Its platform is designed to connect innate and adaptive immunity across cancer, autoimmune disease, and states of severe immune dysfunction.
AgenT-797 Lead Asset
AgenT-797 is an off-the-shelf, cryopreserved iNKT-cell therapy that does not require lymphodepletion or HLA matching. These characteristics may support use in severe acute lung injury, critical illness, and other settings involving immune dysregulation.
Off-the-Shelf Treatment Model
The ability to store and administer AgenT-797 without patient-specific manufacturing is central to its intended use. This model may be particularly relevant in acute-care settings where rapid treatment and simplified logistics are important.
Multi-Indication Expansion
AgenT-797 is being studied in solid tumors, graft-versus-host disease, and critical pulmonary immune failure. MiNK also has TCR-based and neoantigen-targeted iNKT programs intended to achieve tissue-specific immune activation.
Future catalysts
- Additional randomized Phase 2 data for agenT-797 in acute lung injury and ARDS in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MiNK Therapeutics, Inc. (INKT)?
MiNK Therapeutics, Inc. (INKT) most recently closed at 11.71 USD, a +1.04% move versus the previous session.
What is the market cap of MiNK Therapeutics, Inc. (INKT)?
MiNK Therapeutics, Inc. currently has a market capitalization of 59.6M USD on BioPharmSignal.
What does MiNK Therapeutics, Inc. do?
Allogeneic iNKT Cell Therapy Company MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines. Its platform is designed to connect innate and adaptive immunity across cancer, autoimmune disease, and states of severe immune dysfunction. AgenT-797 Lead Asset AgenT-797 is an off-the-shelf,...
On which exchange is INKT stock listed?
MiNK Therapeutics, Inc. (INKT) is associated with NASDAQ, United States, Biopharma.
What is Allogeneic?
Allogeneic iNKT Cell Therapy Company MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines.
Which conditions is MiNK Therapeutics, Inc. targeting with Allogeneic?
MiNK Therapeutics, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does MiNK Therapeutics, Inc. describe recent progress with Allogeneic?
Additional randomized Phase 2 data for agenT-797 in acute lung injury and ARDS in 2027.
What is Cell?
Allogeneic iNKT Cell Therapy Company MiNK Therapeutics develops allogeneic invariant natural killer T-cell therapies and precision immune-modulating medicines.